Role of androgens in abiraterone resistance.
Colloca G, Colloca G.
J Clin Oncol · letter; comment · DOI 10.1200/jco.2012.42.6528 PUBLIKATIONSREGISTRET
Gå till forskningen.
Publikationsdata från Europe PMC och PubMed. Följ källhänvisningar från ämnesregistret till originalpublikationerna.
Publikationer som ChEBI hänvisar till för abiraterone. Visa hela publikationsregistret
En publikationsträff är inte en slutsats. Publikationslistan visar bibliografiska uppgifter. Eventuella forskningsutdrag visas separat med originalunderlag. En källhänvisning visar inte i sig effekt, dosering eller säkerhet.
Publikationer i urvalet
29 träffarNICE guidance on abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Dyer M, Rinaldi F, George E, Adler AI.
Lancet Oncol · news · DOI 10.1016/s1470-2045(12)70289-9Validated RP-HPLC/UV method for the quantitation of abiraterone in rat plasma and its application to a pharmacokinetic study in rats.
Kumar SV, Rudresha G, Gurav S, Zainuddin M, Dewang P, Kethiri RR, Rajagopal S, Mullangi R.
Biomed Chromatogr · journal article · DOI 10.1002/bmc.2776Abiraterone inhibits 3β-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer.
Li R, Evaul K, Sharma KK, Chang KH, Yoshimoto J, Liu J, Auchus RJ, Sharifi N.
Clin Cancer Res · research support, non-u.s. gov't; research support, u.s. gov't, non-p.h.s.; journal article · DOI 10.1158/1078-0432.ccr-12-0908Abiraterone. After prostate cancer treatment failure: 4-month survival advantage.
Författaruppgift saknas
Prescrire Int · journal articleNICE recommends abiraterone for prostate cancer after manufacturer reduces price.
Kmietowicz Z.
BMJ · news · DOI 10.1136/bmj.e3520Words of wisdom. Re: Abiraterone and increased survival in metastatic prostate cancer.
Cheetham PJ, Petrylak DP.
Eur Urol · comment; journal article · DOI 10.1016/j.eururo.2012.01.036The role of abiraterone in the management of metastatic castration-resistant prostate cancer.
Rawlinson A, Mohammed A, Beatty J, Bell R, Miller M.
Expert Rev Anticancer Ther · review; journal article · DOI 10.1586/era.12.12Abiraterone in prostate cancer: a new angle to an old problem.
Stein MN, Goodin S, Dipaola RS.
Clin Cancer Res · research-article; review; journal article · DOI 10.1158/1078-0432.ccr-11-1805Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100.
Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan IJ, de Bono JS, Attard G.
Cancer Res · research support, non-u.s. gov't; research-article; journal article · DOI 10.1158/0008-5472.can-11-3980[Compassionate use of abiraterone and cabazitaxel: first experiences in docetaxel-pretreated castration-resistant prostate cancer patients].
Heck MM, Höppner M, Horn T, Thalgott M, Gschwend JE, Retz M.
Urologe A · journal article · DOI 10.1007/s00120-012-2804-yAbiraterone: current and future use in prostate cancer.
Ryan CJ.
Clin Adv Hematol Oncol · journal articleStructures of cytochrome P450 17A1 with prostate cancer drugs abiraterone and TOK-001.
DeVore NM, Scott EE.
Nature · research-article; journal article; research support, n.i.h., extramural · DOI 10.1038/nature10743Clinical and biochemical consequences of CYP17A1 inhibition with abiraterone given with and without exogenous glucocorticoids in castrate men with advanced prostate cancer.
Attard G, Reid AH, Auchus RJ, Hughes BA, Cassidy AM, Thompson E, Oommen NB, Folkerd E, Dowsett M, Arlt W, de Bono JS.
J Clin Endocrinol Metab · clinical trial; research support, non-u.s. gov't; journal article · DOI 10.1210/jc.2011-2189Development and validation of a highly sensitive method for the determination of abiraterone in rat and human plasma by LC-MS/MS-ESI: application to a pharmacokinetic study.
Gurav S, Punde R, Farooqui J, Zainuddin M, Rajagopal S, Mullangi R.
Biomed Chromatogr · journal article · DOI 10.1002/bmc.1726Words of wisdom. Re: Abiraterone and increased survival in metastatic prostate cancer.
Richie JP.
Eur Urol · journal article · DOI 10.1016/j.eururo.2011.07.033Abiraterone plus prednisone improves survival in metastatic castration-resistant prostate cancer.
Tagawa ST, Beltran H.
Asian J Androl · other; journal article · DOI 10.1038/aja.2011.113Combination therapy: Abiraterone prolongs survival in metastatic prostate cancer.
Sartor O.
Nat Rev Clin Oncol · comment; journal article · DOI 10.1038/nrclinonc.2011.111Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.
Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB.
Clin Cancer Res · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1158/1078-0432.ccr-11-0728Abiraterone and increased survival in metastatic prostate cancer.
Parker C, Sartor O.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1107198Abiraterone and increased survival in metastatic prostate cancer.
Sonpavde G.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1107198Abiraterone and increased survival in metastatic prostate cancer.
Berruti A, Pia A, Terzolo M.
N Engl J Med · letter; comment · DOI 10.1056/nejmc1107198Prostate cancer: Abiraterone increases overall survival in men with castration-resistant prostate cancer.
Fenner A.
Nat Rev Urol · comment; journal article · DOI 10.1038/nrurol.2011.94Synthesis and biological evaluations of putative metabolically stable analogs of VN/124-1 (TOK-001): head to head anti-tumor efficacy evaluation of VN/124-1 (TOK-001) and abiraterone in LAPC-4 human prostate cancer xenograft model.
Bruno RD, Vasaitis TS, Gediya LK, Purushottamachar P, Godbole AM, Ates-Alagoz Z, Brodie AM, Njar VC.
Steroids · research support, non-u.s. gov't; research-article; journal article; research support, n.i.h., extramural · DOI 10.1016/j.steroids.2011.06.002Abiraterone and increased survival in metastatic prostate cancer.
de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Fléchon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators.
N Engl J Med · clinical trial, phase iii; research support, non-u.s. gov't; research-article; multicenter study; randomized controlled trial; journal article · DOI 10.1056/nejmoa1014618Abiraterone and MVD3100 take androgen deprivation to a new level.
Schmidt C.
J Natl Cancer Inst · news · DOI 10.1093/jnci/djr014Use of abiraterone for prostate cancer.
Mohler JL, Pantuck AJ.
J Urol · journal article · DOI 10.1016/j.juro.2010.12.009Phase III data for abiraterone in an evolving landscape for castration-resistant prostate cancer.
Pal SK, Sartor O.
Maturitas · research support, non-u.s. gov't; research-article; editorial; research support, n.i.h., extramural · DOI 10.1016/j.maturitas.2010.10.009Abiraterone in prostate cancer.
Ryan C.
Clin Adv Hematol Oncol · review; journal article